The following trials provide information to treat various types of cancer and infectious disease, both for ongoing and completed clinical trials. For more information on our oncology therapy area please click here or for our infection therapy area please click here.
-
expand
An Open Label, Randomised, Parallel Group, Multicentre Study to Compare ZOLADEX™ 10.8 mg Given Every 12 Weeks with ZOLADEX 3.6 mg Given Every 4 Weeks in Pre-menopausal Women with Oestrogen Receptor Positive Advanced Breast Cancer
- Study Id
- D8666C00001
- Disease
- breast cancer
- Drug Name
- Zoladex
- Study Name
- D8666C00001
- Recruiting Status
- Closed
- Protocol Status
- Not Available
- Report Status
- Not Available
-
expand
A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD3514 in Patients with Metastatic Castration-Resistant Prostate Cancer.
- Study Id
- D3760C00001
- Disease
- prostate cancer
- Study Name
- D3760C00001
- Recruiting Status
- Closed
- Protocol Status
- Not Available
- Report Status
- Not Available
-
expand
A Randomised Double-Blind Placebo-controlled Multicentre Phase I Study to Assess the Biological Activity of AZD8931 in Patients With Early Breast Cancer Who Are Ineligible for Treatment With Trastuzumab as Defined by IHC Status.
- Study Id
- D0102C00019
- Disease
- breast cancer
- Drug Name
- AstraZeneca Oncology and Infection Development Drugs
- Study Name
- D0102C00019
- Recruiting Status
- Closed
- Protocol Status
- Not Available
- Report Status
- Not Available
-
expand
A Phase IIa Multi-centre Randomised Double-Blind Placebo-controlled Study to Assess the Efficacy, Safety and Pharmacokinetics of AZD8931 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Metastatic, Gastric or Gastro-oesophageal Junction, Cancer Who Progress Following First Line Therapy and Are Ineligible for Treatment With Trastuzumab by HER2 Status (SAGE)
- Study Id
- D0102C00006
- Disease
- gastric cancer
- Drug Name
- AZD8931
- Study Name
- D0102C00006
- Recruiting Status
- Closed
- Protocol Status
- Not Available
- Report Status
- Not Available
-
expand
A Phase II, Randomised, Double-blind, Placebo-controlled, Multi-centre Study of AZD8931 In Combination with Anastrozole in Post menopausal Women With Hormone Receptor positive, Endocrine Therapy naive, Locally advanced or Metastatic Breast Cancer (MINT)
- Study Id
- D0102C00004
- Disease
- solid tumour
- Drug Name
- AZD8931
- Recruiting Status
- Closed
- Protocol Status
- Not Available
- Report Status
- Not Available
-
expand
A Multicenter, observational, non-interventional registry designed to collect clinical data in Chinese patients who have received CUBICIN® treatment under condition of actual usage in clinical practice
- Study Id
- NIS-ICN-DUM-2010/1
- Disease
- blood infection
- Drug Name
- Cubicin
- Study Name
- NIS-ICN-DUM-2010/1
- Recruiting Status
- Closed
- Protocol Status
- Not Available
- Report Status
- Not Available
-
expand
A Phase I, Single-center, Randomized, Open-label, Crossover Study to Compare the White (Current Phase II) and Blue (Planned Phase III) Capsule Formulations of AZD6244 Hyd-Sulfate in Healthy Male Subjects.
- Study Id
- D1532C00066
- Disease
- cancer
- Drug Name
- AstraZeneca Oncology and Infection Development Drugs
- Study Name
- D1532C00066
- Recruiting Status
- Closed
- Protocol Status
- Not Available
- Report Status
- Not Available
-
expand
A non-interventional survey on the EGFR mutation status in completely resected Chinese NSCLC patients with adenocarcinoma histology
- Study Id
- NIS-OCN-DUM-2009/1
- Disease
- non-small cell lung cancer
- Drug Name
- non drug study (oncology)
- Study Name
- NIS-OCN-DUM-2009/1
- Recruiting Status
- Closed
- Protocol Status
- Not Available
- Report Status
- Not Available
-
expand
Study to assess safety, tolerability and PK of AZD1480 alone or in comb with Docectaxel in patients with solid tumours
- Study Id
- D1060C00002
- Disease
- solid tumour
- Drug Name
- AZD1480
- Study Name
- D1060C00002
- Recruiting Status
- Closed
- Protocol Status
- Not Available
- Report Status
- Not Available
-
expand
A Phase 1, Multicenter, Open-Label, Single-Arm, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-575, a Fully Human Monoclonal Antibody Directed Against Platelet-Derived Growth Factor Receptor Alpha, in Subjects with Advanced Solid Tumors Refractory to Standard Therapy or for which no Standard Therapy Exists
- Study Id
- MI-CP187
- Disease
- solid tumour
- Drug Name
- MEDI-575
- Study Name
- MI-CP187
- Recruiting Status
- Closed
- Protocol Status
- Not Available
- Report Status
- Not Available
